Home > Insider Trading > Filing (0001104659-17-056988)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1640266	Voyager Therapeutics Inc.	VYGR	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1711276	Bernard Ravina	C/O Voyager Therapeutics 75 Sidney Street Cambridge MA 02139	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-07-20	5,490	$10.00	49,413	No	4	S	Direct
Common Stock	Disposition	2017-09-11	10,980	$14.30	32,943	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
This total reflects the number of shares beneficially owned by the reporting person on July 20, 2017, following the reported transaction.
This total reflects an adjustment for a clerical error on the reporting person's Form 3 wherein the number of shares beneficially owned was inadvertently overstated by 62,744 shares. Such shares were sold prior to Dr. Ravina becoming a reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.95, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
This total reflects the number of shares beneficially owned by the reporting person as of the date hereof, following the reported transaction and inclusive of all intervening transactions.